Design of Adaptive Phase 1 Clinical Trials for Dose Escalation using the DEDUCE Application

The UMB-DF/HCC PArtnership's Research Design and Analysis Core (RDAC) held a seminar on October 27, 2022 featuring speakers Dr. Wendy London, PhD and Clement Ma, PhD.
In this presentation, they share their experience in developing and implementing adaptive dose-finding designs in pediatric oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center. First, they developed the novel Bayesian adaptive TARGETed-agent Continual Reassessment Method (TARGET-CRM) to prioritize the enrollment of children with specific rare tumor mutations who were more likely to benefit from the molecularly-targeted therapy. They then implemented the TARGET-CRM design in two pediatric phase 1 trials. Finally, they describe the DEsign and conDUCt of dose Escalation trials (DEDUCE) web-based app to help investigators design and conduct adaptive trials.
To learn more about RDAC and the Partnership as a whole, visit our website at www.UMB-DFHCC.org.

[@aeky168]

What is advantage of 3+3 design?

[@thepartnership800]

Response from Dr. London: "easy to understand and conduct;
well known in the oncology scientific community;
requires very little time from a statistician, and therefore could be a lower cost"